Company

Merck KGaA

2 active trials that select patients by a biomarker on marked.bio, across 1 biomarker.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

MET exon 14 skipping1

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

tepotinib 1

Trials

2 of 11 trials shown

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

Active, not recruiting Phase 1/2 Merck KGaA Started 2025Primary completion 2027-12 NCT06710132

M9140

…essing EGFR tumors (including participants with any driver genomic alterations other than EGFR mutations

EGFR exon 19 deletion / L858RSolid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

Active, not recruiting Phase 2 Merck KGaA Started 2016Primary completion 2022-05 NCT02864992

tepotinib FDA EU

Participants with MET alterations, namely METex14 skipping alterations in plasma and/or tissue as determined by the central laboratory or b…

MET exon 14 skippingAdvanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Completed Phase 2 Merck KGaA Started 2024 NCT06433219

Tuvusertib (M1774)niraparib FDA EULartesertib (M4076)

…n With the PARP Inhibitor Niraparib or the ATM Inhibitor Lartesertib in Participants With BRCA Mutant and/or Homologous Recombination deﬁciency (HRD)-Positive Epithelial Ovarian Cancer That P…

BRCA1/2 mutationOvarian Cancer
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

Completed Phase 2 Merck KGaA Started 2019 NCT03940703

tepotinibosimertinib FDA EU

…otinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)

EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer
Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)

Completed Phase 1/2 Merck KGaA Started 2013 NCT01982955

tepotinibgefitinib FDA EUpemetrexedcisplatincarboplatin

…e Treatment in Subjects With MET Positive, Locally Advanced or Metastatic NSCLC Harboring EGFR Mutation and Having Acquired Resistance to Prior EGFR-TKI Therapy (INSIGHT)

EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Completed Phase 2 Merck KGaA Started 2012 NCT01693068

Pimasertibdacarbazine

…ally confirmed, locally advanced or metastatic cutaneous melanoma (stage III c or M1ac) N-Ras mutated.

KRAS G12CKRAS G12DN-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma
Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer

Completed Phase 2 Merck KGaA Started 2011 NCT01388790

cetuximabcisplatinS-1

… standardized epidermal growth factor receptor (EGFR) expression and Kirsten-rat sarcoma (KRAS) mutation assessments

KRAS G12CKRAS G12DGastric Cancer
Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype

Completed Phase 2 Merck KGaA Started 2011 NCT01450319

cetuximab

Histological confirmed colorectal cancer (CRC) with mutated K-RAS and favorable genotypes (any H in FcγRIIa-131).

KRAS G12CKRAS G12DColorectal Neoplasms
MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)

Terminated Phase 1/2 Merck KGaA Started 2010 NCT01085331

PimasertibFOLFIRI

Histologically confirmed K-Ras mutated colon/rectum cancer

KRAS G12CKRAS G12DMetastatic Colorectal Cancer
M1231 in Participants With Solid Tumors

Completed Phase 1 Merck KGaA Started 2021 NCT04695847

M1231

…sed on at least 1 prior line of platinum therapy and for microsatellite instability-high (MSI-H) at least 1 prior line with pembrolizumab

MSI-H / dMMRMetastatic Solid Tumors, Esophageal Cancer, Non-Small Cell Lung Cancer
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors

Completed Phase 1 Merck KGaA Started 2011 NCT01390818

MSC1936369B (pimasertib)SAR245409 (PI3K and mTOR inhibitor)

Relapsed or refractory metastatic colorectal cancer (CRC) with dual KRAS and PIK3CA mutation with no approved therapies, or

KRAS G12CKRAS G12DBRAF V600EPIK3CA activating mutationLocally Advanced Solid Tumor, Metastatic Solid Tumor, Breast Cancer, Non Small Cell Lung Cancer